We are international

Sydney 2005:
New Antiangiogenic Agents
By Guido Tricot, MD

Dr. Tricot continued the presentations by reviewing recent studies on new antiangiogenic agents. In a dose escalation trial, one third of patients achieved a partial remission and approximately one third of patients had a 5-year event-free survival (EFS) with few having evidence of disease at more than 6 years. A trial with Revlimid in patients, most of who had relapsed after autotransplantation, showed an EFS of 43% and an overall survival of 66%. The most common toxicity observed was thrombocytopenia. Another trial is looking at the combination therapy revlimid, thalidomide (dose escalated), and dexamethasone. In this trial, 60% of patients had greater than a 50% response. No correlation between thalidomide dose and event free survival was seen. Commonly observed toxicities were mainly hematological events. These studies suggest that combination therapy may provide the best response.

Back to session summary

 related articles